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Autophagy is biological mechanism allowing recycling of
long-lived proteins, abnormal protein aggregates, and damaged
organelles under cellular stress conditions. Following seques-
tration in double- or multimembrane autophagic vesicles, the
cargo is delivered to lysosomes for degradation. ATG5 is a key
component of an E3-like ATG12-ATG5-ATG16 protein com-
plex that catalyzes conjugation of the MAP1LC3 protein to lip-
ids, thus controlling autophagic vesicle formation and expan-
sion. Accumulating data indicate that ATG5 is a convergence
point for autophagy regulation. Here, we describe the scaffold
protein RACK1 (receptor activated C-kinase 1, GNB2L1) as a
novel ATG5 interactor and an autophagy protein. Using several
independent techniques, we showed that RACK1 interacted
with ATG5. Importantly, classical autophagy inducers (starva-
tion or mammalian target of rapamycin blockage) stimulated
RACK1-ATG5 interaction. Knockdown of RACK1 or preven-
tion of its binding to ATG5 using mutagenesis blocked
autophagy activation. Therefore, the scaffold protein RACK1 is
a new ATG5-interacting protein and an important and novel
component of the autophagy pathways.
Autophagy is a highly conserved biological mechanism that
is responsible for lysosome-dependent recycling of long-lived
abnormal or misfolded proteins as well as dysfunctional or
unnecessary organelles (such as depolarizedmitochondria) (1).
Under normal conditions, basal autophagy help maintain cel-
lular homeostasis. Autophagy is rapidly up-regulated following
stress, including nutrient deprivation, accumulation of mis-
folded proteins, mitochondrial depolarization, or exposure to
toxic chemicals (2). Autophagy malfunctions were shown to
contribute to several pathologies, such as neurodegenerative
diseases, lysosomal storage disorders, and cancer (3).
The process startswith the nucleation and elongation of dou-
ble-membrane structures called “autophagosomes” or
“autophagic vesicles.” As they mature through fusion with late
endosomes or lysosomes, vesicles give rise to “autolysosomes,”
a hybrid compartment in which vesicle contents are degraded
by the action of lysosomal hydrolases (4). So far, around 33
different core autophagy proteins (ATGs) were described (5).
Among them, two ubiquitination-like reactions are key to
autophagic vesicle membrane elongation as follows: ATG12-
ATG5-ATG16L1 and ATG8 (MAP1LC3 or shortly LC3 in
mammals). The first ubiquitination-like reaction results in the
covalent conjugation of a Lys-130 residue of the ATG5 protein
to a ubiquitin-like protein, ATG12. Following addition of
ATG16L1 to theATG12-conjugatedATG5, a larger complex of
around 669–800 kDa forms (6). The ATG12-ATG5-ATG16L1
complex serves as an E3-like enzyme for the second ubiquity-
lation-like reaction. Here, the LC3 protein is covalently
attached to a lipid molecule, generally to a phosphatidyletha-
nolamine contributing to the elongation of autophagic mem-
branes (7, 8). Conversion of the free cytosolic form of LC3
(LC3-I) to the lipid-conjugated form (LC3-II) leads to its local-
ization to dot-like autophagosome structures in the cytosol and
changes its mobility in SDS-polyacrylamide gels (9). ATG5 and
LC3 conjugations systems are required for the canonical
autophagy pathway to proceed, and abnormalities result in
autophagy defects (10).
mTOR9 serine/threonine kinase is an important upstream
regulator of the autophagy pathway.mTOR-containing protein
complexes (namely mTORC1 and mTORC2) sense and inte-
grate signals, including amino acid, growth factor, and ATP
availability, and regulate cellular responses. mTORC1 complex
regulates cellular growth and protein synthesis through activa-
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tion of its downstream targets, including p70 S6 kinase
(p70S6K) and 4EBP protein. mTORC1 activity directly inhibits
the autophagy pathway through its effect on the ULK1/2
autophagy protein complex (11). In case of deprivation of the
above-mentioned factors, mTOR activity is blocked, allowing
the ULK1/2 complex to function. Hence, chemical inhibitors of
mTOR activity, such as rapamycin or torin 1, strongly activate
autophagy.
Recent studies showed that WD domain-containing pro-
teins, such as ATG16L1, ALFY, and WIPI1, play significant
roles in different stages of the autophagy pathway (12–16). In
this study, we describe RACK1 (receptor-activated C-kinase 1,
GNB2L1), a WD40 repeat protein with a seven-bladed -pro-
peller structure, as an interaction partner of ATG5 and a novel
autophagy protein. RACK1 was originally characterized as a
scaffold/adaptor protein that binds to protein kinase C (PKC)
isoforms (17). Since then, several non-PKC partners of RACK1
were described as well, and the protein was involved in the
regulation of a variety of cellular functions, including prolifer-
ation, migration, apoptosis, angiogenesis, and protein transla-
tion (18).
Here, we showed that RACK1-ATG5 interaction was regu-
lated by autophagy-inducing signals, namely starvation and
mTOR inhibition. Importantly, we provide evidence that
RACK1 protein itself and the RACK1-ATG5 interaction were
indispensable for autophagy induction. Using chemical inhibi-
tors and genetic approaches, we mapped signaling events reg-
ulating RACK1-ATG5 interaction downstream to the
mTOR/p70 S6 kinase pathway. Therefore, our data show
that RACK1 is a new and dynamic component of the core
autophagy machinery.
Results
RACK1 Is a Novel ATG5 Interaction Partner—To discover
novel ATG5 interactors and autophagy-related proteins, we
performed a yeast two-hybrid (Y2H) screen using ATG5 as a
bait. At least three different clones of RACK1 (GNB2L1) were
found to interact with the autophagy protein. The results of the
Y2H screen will be described in detail elsewhere.10
To confirm the interaction, we cloned full-length RACK1
cDNA into a mammalian expression vector. Following overex-
pression experiments in HEK293T cells, we could show that
immunoprecipitated ATG5 could pull down the RACK1 pro-
tein (Fig. 1A). Conversely, RACK1 immunoprecipitation
resulted in the pulldown of ATG5 (Fig. 1B).We could also con-
firm the interaction between the endogenous proteins inmouse
embryonic fibroblast (MEFs) cells (Fig. 1, C and D). Moreover,
we could validate that the two proteins interacted directly in
GST pulldown in vitro binding assays using recombinant pro-
teins (Fig. 1E). Finally, examination of cells using confocal
microscopy under basal fed conditions (culture in DMEM plus
10% FBS) showed that both proteins were partially colocalized
in cytoplasmic dots (Fig. 1, F and G). All these data indicated
that RACK1 is a novel ATG5-interacting protein. Dynamic Nature of ATG5-RACK1 Interaction under
Autophagy-inducing Conditions—To further confirm the
ATG5-RACK1 interaction, we performed gel filtration experi-
ments with endogenous protein extracts using a gel filtration10 S. Erbil and D. Gozuacik, manuscript in preparation.
FIGURE 1.RACK1 is a novel ATG5 interactor. A, HEK293T cells were cotrans-
fected with plasmids encoding FLAG-tagged ATG5 and/or non-tagged full-
length RACK1proteins. 48 h after transfection, IPwere performedusing FLAG
beads. Anti-ATG5 and anti-RACK1 antibodies were used for immunoblotting.
Input, total cell extract; IgG, immunoglobulin G. Molecular mass is shown in
kilodaltons (kDa). -Actin was used as loading control. B, HEK293T cells were
cotransfected with FLAG-RACK1 and/or non-tagged ATG5 constructs, and
immunoprecipitations were performed using FLAG beads. C, endogenous
ATG5 protein was immunoprecipitated from wild-type MEF cell extracts
using anti-ATG5 antibodies that were coupled to protein A Plus beads. Anti-
ATG5 and anti-RACK1 antibodies were used for immunoblotting. Serum, con-
trol rabbit serum. D, endogenous RACK1 protein was immunoprecipitated
from wild-type MEF cell extracts using anti-RACK1 antibodies that were cou-
pled toproteinGPlusbeads.Anti-ATG5andanti-RACK1antibodieswereused
for immunoblotting. Serum, control mouse serum. E, GST pulldown assay.
Glutathione-Sepharose beads that were bound to GST-ATG5 recombinant
protein or not were incubated with His-RACK1 recombinant protein and
washed. Input, immunoblotting of recombinant proteins; GST pulldown, pro-
teins after pulldown. Note that His-RACK1 did not bind to beads alone. F,
HEK293T cells were cultured on coverslides and cotransfected with GFP-
tagged RACK1 (green) and Cherry-tagged ATG5 (red) constructs. 48 h post-
transfection, cells were fixed and analyzed under a confocal microscope.
Merge, overlayofgreen and red signals.White arrows showyellowcytoplasmic
dots formed by RACK1 and ATG5 colocalization. G, non-transfected HEK293T
cells were cultured on coverslides. After 72 h of incubation, cells were fixed,
and endogenous RACK1 and ATG5 proteins were immunostained using anti-
RACK1 and anti-ATG5 primary antibodies. Anti-mouse IgG Alexa Fluor 488
(green) or anti-rabbit IgG Alexa Fluor 568 (red) were used as secondary anti-
bodies, respectively. Cellswereanalyzedunder a confocalmicroscope.Merge,
overlay of green and red signals. White arrows show yellow cytoplasmic dots
formed by RACK1 and ATG5 colocalization.
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columnwith a separation range between 5 and 5000 kDa. In line
with the published data (12, 19), the endogenous ATG12-5-16
complex was eluted from the column at 669–800-kDa frac-
tions. Endogenous RACK1 protein was mostly absent in
ATG12-5-16- containing fractions under fed conditions in
HEK293T (Fig. 2A, CNT) and Neuro2A (N2A) (Fig. 2B, CNT)
cells. Importantly, upon autophagy activation using an mTOR
inhibitor, torin 1 (Fig. 2, A and B), the amount of RACK1 pro-
tein thatwas recovered in fractions containing theATG12-5-16
complex was significantly increased.
Tri-SILAC labeling and LC-MS/MS analysis was performed
following immunoprecipitation of a FLAG-tagged ATG5 pro-
tein from cells. Using this technique, we could confirm ATG5-
RACK1 interaction under autophagy-stimulating conditions
(Fig. 2I).
Immunoprecipitation assays supported the data as well.
Indeed, the RACK1-ATG5 interaction was prominently
increased following treatment of cells with mTOR inhibitors
rapamycin or torin 1 (Rapa, Torin, Fig. 3,A andC). Starvation of
cells stimulated the interaction between two proteins as well
(Stv, Fig. 3, B and C).
To check the intracellular localization of RACK1-ATG5
interaction following autophagy activation, we performed con-
focal microscopy analyses. Treatment of cells with rapamycin
or torin 1, or starvation led to an increase in the number of
dot-like structures where ATG5 and RACK1 colocalized (Fig.
3D) Moreover, RACK1-positive dots colocalized with the
autophagosome marker LC3 (Fig. 3E), indicating that these
structures truly represent autophagosomes (20).
RACK1 Is Required for Autophagy Activation Following
mTOR Inhibition and Starvation—Interaction of RACK1 with
an autophagy-related protein complex and in an autophagy
stimulus-dependentmanner indicated that RACK1 could be an
important component of autophagy regulation. Alternatively,
FIGURE 2.RACK1 is a novel component of a large ATG12-5-16 protein complex. A, non-transfected HEK293T cell were treated with torin 1 or DMSO carrier
control, and total cell lysates were fractioned in a gel filtration column. Chromatography fractions (F1–13) were separated in SDS-polyacrylamide gels and
immunoblotted using anti-ATG16, anti-ATG5, and anti-RACK1 antibodies. CNT, DMSO carrier control; TORIN, torin 1 treatment (250 nM, 3 h); ATG16, ATG16L1;
L, total cell lysate; F1 and F2, 800-kDa fractions; F3–6, 800–669-kDa fractions; F7–10, 669–443-kDa fractions; F11 and F12, 443–200-kDa fractions; F13,
200–150-kDa fraction. No protein complexes were detected in lower molecular weight fractions. B, N2A cell were treated with torin 1 or DMSO carrier control,
and total cell lysateswere fractioned in a gel filtration column as in A. C, chromatogram showing peaks of themolecular weightmarkermix (Sigma, catalog no.
MWGF1000);Ve, elutionvolume.D,OD595 absorbanceconfirmationof thepeaks.E, standardizationof thegel filtrationcolumnbyVe/V0.V0, voidvolume. F, curve
showing correlation of fractions with protein sizes in kDa. G and H, representative chromatograms obtained for HEK293T (G) and N2A (H) cell lines. I, Tri-SILAC-
LC-MS/MSanalyses. ATG5enrichment comparedwithbeads alone (upper panel); enrichmentof RACK-ATG5complexunder torin-treated conditions compared
with DMSO-treated control (lower panel) (mean S.D. of independent experiments, n 3, *, p 0.05).
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RACK1 could be an autophagy target that was recruited to
autophagosomes through its interaction with autophagy
proteins.
To determine the importance of RACK1 in autophagymech-
anisms, we knocked down RACK1 using specific siRNAs and
quantified autophagy activation levels using LC3 dot quantifi-
cation analyses. In cells transfected with a control siRNA (CNT
siRNA), mTOR inhibition or starvation strongly induced
autophagy (around 4–5 times basal levels). Strikingly, knock-
down of RACK1 under the same conditions significantly atten-
uated autophagy induction by these stimuli (Fig. 4, A and B).
Moreover, knockdown of RACK1 prevented LC3-II formation
and led to an accumulation of LC3-I in immunoblots. In line
with this, p62 degradation that was observed in extracts from
CNT siRNA-transfected cells was abolished following RACK1
down-regulation (Fig. 4A). Under these conditions, addition of
bafilomycinA (an inhibitor of autophagosome-lysosome fusion
blocking autolysosomal degradation) led to LC3-II accumula-
tion in controls and could block p62 degradation. In contrast,
bafilomycin A did not cause further p62 or LC3-II accumula-
tion in extracts from cells with RACK1 knockdown (Fig. 4A).
All these results indicate that RACK1 is involved in upstream
stages before autophagosome-lysosome fusion and autolyso-
some formation.
To detect whether RACK1 could be an autophagy target, we
stimulated autophagy using rapamycin or starvation in the
absence or presence of translation inhibitor cycloheximide or
bafilomycin A, and we checked endogenous RACK1 protein
levels (Fig. 4, C and D). None of these treatments resulted in
RACK1 degradation even at longer incubation times (24-h ra-
pamycin treatment or 8-h starvation), and independent of
cycloheximide treatment, bafilomycin A treatment did not
result in significant RACK1 accumulation. Therefore, RACK1
itself is not degraded by autophagy, but it is required for
autophagy induction by classical autophagy stimuli, i.e.mTOR
inhibition and starvation.
mTOR and p70S6K Regulate RACK1-ATG5 Interaction—
Because inhibition ofmTOR resulted in an increase in RACK1-
ATG5 interaction, we wondered whether RACK1-ATG5 inter-
action was regulated by mTOR itself or proteins that function
downstream to mTOR.
We overexpressed mTOR protein and checked RACK1-
ATG5 interaction in co-immunoprecipitation assays. Under
these conditions, we observed that overexpression of the
FIGURE 3. Dynamic nature of RACK1-ATG5 interaction under autophagy-inducing conditions. A, HEK293T cells were cotransfected with FLAG-ATG5
and/or non-taggedRACK1 constructs and treatedor notwith rapamycin (Rapa, 200nM, 16h) or torin 1 (Torin, 250nM, 3h). IPwereperformedusingFLAGbeads.
Anti-ATG5 and anti-RACK1 antibodieswere used for immunoblotting. Input, total cell extract; IgG, immunoglobulin G.Molecularmass is shown in kDa.-Actin
was used as loading control. Band intensities were quantified using ImageJ. B, HEK293T cells were cotransfected with FLAG-RACK1 and/or non-tagged ATG5
constructs and starved in EBSS (2 h) or not. Anti-ATG5 and anti-RACK1 antibodies were used for immunoblotting. C, HEK293T cells were treated or not with
rapamycin (Rapa,200nM, 16h)or torin1 (Torin, 250nM, 3h), or starved inEBSS (2h). EndogenousATG5proteinwas immunoprecipitated fromcell extractsusing
anti-ATG5 antibodies that were coupled to protein A Plus beads. Anti-ATG5 and anti-RACK1 antibodies were used for immunoblotting. Serum, control rabbit
serum. D, HEK293T cells were cultured on coverslides. They were treated or not with rapamycin (Rapa, 200 nM, 16 h) or torin 1 (Torin, 250 nM, 3 h), or starved in
EBSS (Stv, 2 h) or not. Then endogenous proteins were immunostained using anti-RACK1 and anti-ATG5 primary antibodies. Anti-mouse IgG Alexa Fluor 488
(green) and anti-rabbit IgG Alexa Fluor 568 (red) were used as secondary antibodies, respectively. Cells were analyzed under confocal microscope. CNT,
non-treated cells; Merge, overlay of green and red signals. White arrows show yellow cytoplasmic dots with RACK1 and ATG5 colocalization. E, HEK293T cells
were culturedon coverslides. Cellswere treatedor notwith rapamycin (Rapa, 200nM, 16 h) or torin 1 (Torin, 250nM, 3 h), or starved in EBSS (Stv, 2h) or not. Then
endogenous proteins were immunostained by using anti-RACK1 and anti-LC3 primary antibodies. Cells were analyzed under a confocal microscope. CNT,
non-treated cells; Merge, overlay of green and red signals. White arrows show yellow cytoplasmic dots with RACK1 and LC3 co-localization.
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mTOR kinase resulted in a decrease in RACK1-ATG5 interac-
tion (Fig. 5A). In line with data obtained using chemical inhib-
itors, knockdown of mTOR using specific shRNAs resulted in
an increase in RACK1-ATG5 interaction (Fig. 5B).
p70S6 kinase is a major serine/threonine kinase that func-
tions downstream to mTOR. To check whether p70S6K played
a role in the regulation of RACK1-ATG5 interaction, we first
overexpressed a wild-type kinase (21). Indeed, overexpression
of the kinase led to the dissociation of RACK1 fromATG5 (Fig.
5C). To further confirm that p70S6K protein itself was neces-
sary for the observed effects on the interaction, we transfected
cells with specific siRNAs. Indeed, knockdown of p70S6K pro-
moted association of RACK1 with its partner ATG5 (Fig. 5D).
All these results showed that RACK1-ATG5 interaction is reg-
ulated by mTOR in a p70S6K-dependent manner.
Determination of RACK1 Amino Acid Residues That Are
Critical for the Interaction—In a study searching for S6 kinase
targets using a phospho-proteomics screen, Jastrzebski et al.
(22) found that four serine or threonine residues in RXX(S/T)
consensus sequences on RACK1 could be phosphorylated in a
rapamycin-sensitive and S6 kinase-dependent manner. When
we compared RACK1 amino acid sequences from different
organisms from yeast to man, we observed that three of these
consensus sequences were highly conserved (consensus
sequences containing residues Thr-39, Ser-63, and Thr-128)
(Fig. 6A). We have mutated these Ser/Thr residues to alanine
mimicking the dephosphorylated state (Fig. 6B), or to aspartic
acid mimicking the phosphorylated state. We then performed
ATG5 immunoprecipitation assays and checked its interaction
with wild-type (WT) or alanine mutant RACK1 proteins
FIGURE 4. RACK1 is required formTOR inhibition and starvation-induced autophagy, but it is not an autophagy target. A, HEK293T cells were cultured
on coverslides and transfected with siRACK1 or control siRNA (CNT siRNA). 48 h post-transfection, cells were treated or not () with rapamycin (Rapa, 200 nM,
16h) or starved in EBSS (2h) in thepresenceor absenceof BafA (100nM, 1h). Endogenous LC3proteinswere immunostainedusing anti-LC3primary antibodies
and anti-rabbit IgG Alexa Fluor 488 secondary antibodies. LC3 dot positive cells were quantified as percentage of autophagic cells in total cell population
(mean S.D. of independent experiments, n 3, *, p 0.05; **, p 0.01). Endogenous protein expression levels were checked in cell extracts from the same
experiments using anti-p62, anti-LC3, and anti-RACK1 antibodies. Molecular mass is shown in kilodaltons (kDa). -Actin was used as loading control. Band
intensities were quantified using ImageJ. B, representative immunofluorescence pictures of LC3 quantification experiments in A. (), non-treated cells. White
arrows show LC3 dots. C, HEK293T cells were treated with rapamycin (200 nM) for 12 or 24 h or with carrier DMSO (D, 24 h) or starved for 2, 4, or 8 h in EBSS or
cultured in full medium (CNT) with or without of BafA (100 nM, 1 h) in the presence of translation inhibitor cycloheximide (0.5 g/ml). Immunoblots were
performed using anti-p62, anti-RACK1, or anti-LC3 antibodies. -Actin was used as loading control. D, HEK293T cells were treated with rapamycin (200 nM) for
12 or 24 h or with carrier DMSO (D, 24 h) or starved for 2, 4, or 8 h in EBSS or cultured in full medium (CNT) with or without of BafA (100 nM, 1 h) in the absence
of translation inhibitor cycloheximide. Immunoblots were performed using anti-p62, anti-RACK1, or anti-LC3 antibodies. -Actin was used as loading control.
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(T39A, S63A, or T128A mutants). As shown in Fig. 6C,
although the interaction of ATG5 was prominently increased
with RACK1 T39A and T128A mutants, S63A mutation com-
pletely abolished RACK1-ATG5 binding.
RACK1 Ser-63 residue is located in the WD40 repeat 2
region (Fig. 7A).We used docking andMD simulations to deci-
phermolecularmechanisms of the interaction betweenRACK1
and ATG5, and particularly the role of Ser-63 in this interac-
tion. Haddock (High Ambiguity-Driven protein-protein dock-
ing) is among the most widely used protein-protein docking
algorithms. The tool proved itself for prediction of structures of
unknown protein-protein complexes. Using that tool, RACK1-
ATG5 was modeled, and the residues found within 3 Å of the
other subunit were selected as the binding interface (Fig. 7B,
ATG5 residues are in green and RACK1 are in yellow). The
predicted protein-protein complex structure was found to pos-
sess a network of salt bridge interactions that were formed by
Asp-4–His-62, Asp-6–Lys-38, Asp-163–His-64, of which neg-
atively charged aspartic acids belong to ATG5, and positively
charged residues (Lys and His) belong to RACK1 (Fig. 7C).
Moreover, the backbone amide group of Ser-63 in RACK1
forms a hydrogen bond with one of the O of Asp-6 in ATG5
(Fig. 7C). Along with this direct involvement of Ser-63 in
RACK1-ATG5 interactions, Ser-63might indirectly contribute
to salt bridge interactions by taking part in positioning the his-
tidines (62 and 64) of RACK1. Overall, the data presented here
unveil a network of interactions in which a pivotal role for
Ser-63 might be suggested.
Further structural information about the role of Ser-63 of
RACK1was collected fromMDsimulations of the native Ser-63
or S63A and S63Dmutant complexes. The r.m.s.d. of backbone
atoms of the complex converged to a plateau and oscillated less
than the 2Å range, suggesting equilibration of the protein com-
plexes (Fig. 7G). Moreover, the simulation data showed that
S63A mutation led to the loss of Asp-6-Lys-38 interaction,
whereas the native and S63D complexes possessed the Asp-6-
Lys-38 interaction (Fig. 7,D–F). In linewith these observations,
fluctuations of ATG5 in the S63A complex have increased, par-
ticularly for the regions 32–36 and 50–54, that were also found
at the binding interface (Fig. 7H). Increased mobility of the
interface in the S63A mutant indicated destabilization of the
complex compared with native Ser-63 and S63D complexes
(Fig. 7H). Overall, computational analyses confirmed the role
played by Ser-63 and also provided insights into the molecular
machinery of RACK1-ATG5 interaction.
RACK1-ATG5 Interaction Was Necessary for mTOR Inhibi-
tion- or Starvation-induced Autophagy—To check whether
RACK1-ATG5 interaction is important for autophagy activa-
tion or not, we expressed wild-type, S63A, or S63D mutant
RACK1 N2A cells (Fig. 8, A–D), and we quantified autophagy
activation by torin 1 and starvation in the absence or presence
of bafilomycin A. LC3 dot quantification under control condi-
tions (pcDNA3 expression) showed that torin 1 and starvation
led to a strong and clear autophagy activation (2 to 3 times basal
level) (Fig. 8,A–D). Interestingly, althoughwild-typeRACK1or
S63D mutant expression further increased the amplitude of
torin 1 or starvation-induced autophagy and LC3-II formation
on immunoblots, expression of the S63A mutant significantly
and reproducibly inhibited LC3 dot numbers in cells and
LC3-II formation in blots (Fig. 8, A–D). Bafilomycin A treat-
ment under these conditions did not prominently lead to accu-
mulation of LC3 dots, yet in blots an increase in LC3-II levels
was observed in wild-type RACK1 or S63Dmutants expressing
cell extracts. No significant LC3-II accumulation was observed
in the S63A mutant expressing cells following bafilomycin A
treatment, underlining the fact that autophagosome formation
was perturbed by this mutant.
We also tested whether wild-type RACK1 or its mutants
could rescue autophagic activity in cells with RACK1 knock-
down. However, the wild-type protein or the S63D mutant
could reverse autophagy inhibition that was observed following
RACK1 knockdown, and the S63A mutant did not show the
same effect (Fig. 9, B and C). Inhibition of lysosomal protease
activity with E64d/pepstatinA led to an accumulation of LC3-II
in wild-type protein or the S63D mutant-transfected cells
but not in cells expressing the S63A mutant (Fig. 9B). There-
fore, the S63A mutant that does bind ATG5 was unable to
rescue an autophagy defect caused by endogenous RACK1
down-regulation.
FIGURE 5. Role of mTOR-p70S6K pathway in the regulation of RACK1-
ATG5 interaction. A, HEK293T cells were cotransfected with FLAG-ATG5
and/or non-tagged RACK1 constructs and/or an mTOR construct. IP were
performed using FLAG beads. Anti-mTOR, anti-ATG5, and anti-RACK1 anti-
bodies were used for immunoblotting. Input, total cell extract; IgG, immuno-
globulin G. Molecular mass is shown in kilodaltons (kDa).-Actin was used as
loading control. Band intensities were quantified using ImageJ. B, HEK293T
cells were cotransfected with FLAG-RACK1 and/or non-tagged ATG5 con-
structs and/or an shmTOR construct. IP were performed using FLAG beads.
Anti-mTOR, anti-ATG5, and anti-RACK1 antibodies were used for immuno-
blotting. C, HEK293T cells were cotransfected with FLAG-RACK1 and/or non-
tagged ATG5 and/or p70S6K wild-type (WT) constructs. IP were performed
using FLAG beads. Anti-p70S6K, anti-ATG5, and anti-RACK1 antibodies were
used for immunoblotting. D, HEK293T cells were cotransfected with FLAG-
ATG5 and non-tagged RACK1 constructs and/or sip70S6 RNAi. Anti-p70S6K,
anti-ATG5, and anti-RACK1 antibodies were used for immunoblotting.
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These results clearly showed that RACK1-ATG5 interaction
is required for autophagy induction by classical autophagy
inducing stimuli, i.e.mTOR inhibition and starvation.
Discussion
In this study, we showed that RACK1 protein is an interac-
tion partner of the key autophagy proteinATG5.We confirmed
this observation using various independent techniques, i.e.
yeast two-hybrid, co-immunoprecipitation tests, confocal
microscopy, SILAC analyses, and gel filtration assays, and we
validated our results in three different cell lines (HEK293T,
MEF, and Neuro2A). In fact, we showed that endogenous
RACK1 was included in a previously reported autophagy-re-
lated 669–800-kDa protein complex containing ATG12-5-16
(19).
Importantly, RACK1-ATG5 interaction was a dynamic one.
Treatment of cells with classical autophagy inducers rapamycin
and torin 1 (mTOR inhibitors) and starvation stimulated
RACK1-ATG5 interaction in cytoplasmic dot-like structures,
indicating that under autophagy-inducing conditions, the
interaction occurred on ATG5 containing isolation mem-
branes. Indeed in previous proteomics analyses, RACK1 was
detected in isolated LC3-positive autophagic vesicles (23). To
rule out the possibility that RACK1 protein itself could be an
autophagy target, we performed kinetic autophagy experiments
in the absence or presence of the protein translation inhibitor
cycloheximide and bafilomycin A. We observed no significant
degradation even at latest time points. Therefore, RACK1 is not
an autophagy target protein, and its association with the
autophagy machinery should have a functional role.
In line with this idea, we observed that RACK1 was required
for autophagic vesicle formation, and knockdown of RACK1
attenuated formation of LC3-positive autophagosomes. Inter-
action of RACK1 with ATG5 was a key event in autophagy
regulation. Amutant RACK1 that could no longer interact with
ATG5 (the S63A mutant) blocked autophagy induced by
mTOR inhibitors or starvation. Data presented here showed
that RACK1 is an essential component of the autophagy
machinery, and its interactionwithATG5 is a critical event that
recruits it to the autophagy pathway.
The mTOR signaling pathway is one of the major regulators
of autophagy. mTOR kinase complexes sense various upstream
stimuli (ATP or amino acid depletion, growth factor depriva-
tion, etc.) and serve asmaster regulators of cellular anabolic and
catabolic pathways. For example, under nutrient- and growth
factor-rich conditions, activation of mTOR complex 1
(mTORC1) results in the phosphorylation and activation of the
p70S6K and eIF4BP (eukaryotic translation initiation factor-4E
binding protein), stimulating protein synthesis and cell survival
(24). Conversely, inhibition of mTOR strongly activates
autophagic protein degradation. In our system, overexpression
of the mTOR kinase or p70S6K led to the dissociation of the
RACK1-ATG5 complex. In addition to data obtained using
mTOR inhibitors rapamycin and torin 1, knockdown of the
mTOR kinase itself or p70S6K stimulated RACK1-ATG5 asso-
FIGURE 6. Determination of RACK1 amino acid residues that are critical for the interaction. A, Clustal Omega alignments of RACK1 protein sequences.
Putative p70S6K target RXX(S/T) consensus sequences are highlighted in black boxes. Ser/Thr residue numbers are marked according to Homo sapiens protein
sequences. RACK1 GenBankTM reference sequences are as follows: H. sapiens, NP_006089; Mus musculus, NP_032169; Danio rerio, NP_571519; Drosophila
melanogaster, AAB72148; Caenorhabditis elegans, NP_501859; Saccharomyces cerevisiae, NP_013834. B, schematic depiction of RACK1 constructs. WD1–7,
WD40 domains 1–7. WT RACK1, wild-type RACK1. T39A, S63A, or T128A, mutant RACK1 constructs. Mutated residues were marked. C, HEK293T cells were
cotransfected with FLAG-ATG5, non-tagged WT RACK1 or T39A, S63A, T128A RACK1 mutant constructs. IPs were performed using FLAG beads. Anti-ATG5 and
anti-RACK1 antibodies were used for immunoblotting. Input, total cell extract; IgG, immunoglobulin G. Molecular mass is shown in kilodaltons (kDa). -Actin
was used as loading control. Band intensities were quantified using ImageJ.
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ciation. Our results indicate that RACK1-ATG5 association
control is one of the mechanisms used by the mTORC1-p70S6
kinase pathway to regulate autophagy.
In fact, RACK1 Ser-63 and other residues, including Thr-39
and Thr-128, were previously suggested to be targets of S6
kinase isoforms (22). Conversion of Ser-63 to alanine (S63A
mutation) on RACK1, mimicking a non-phosphorylated form,
was sufficient to abolish RACK1-ATG5 interaction and to
inhibit mTOR-related or starvation-induced autophagy.More-
over, the S63A mutant could not rescue autophagy inhibition
following RACK1 knockdown. On the one hand, T39A/T39D
or T128A/T128D mutants did not dissolve the RACK1-ATG5
complex. On the other hand, RACK1 T39A and T128A muta-
tions did result in an increased interaction. Yet, different from
the S63A mutant, expression of T39A and T128A mutants or
their phospho-mimicking aspartic acid (T39D and T128D)
forms did not lead to any change in the autophagic activity.11
These results indicated that, an optimum level of RACK1-
ATG5 interaction is necessary and sufficient for autophagy.
Our results showed that both mTOR and p70S6K proteins
were necessary for the regulation of RACK1-ATG5 interaction,
and overexpression of kinase-activemTOR or p70S6K proteins
had an inhibitory effect on complex formation. Nevertheless,
our studies using mutants did not confirm autophagy-related
relevance of a direct phosphorylation of RACK1 on previously
reported p70S6K putative target residues (22). On the contrary,
modification of a critical serine to a non-phosphorylatable form
(S63A) was the only mutation that had a significant effect on
autophagy activation. Therefore, further studies are required to
determine kinase(s) or phosphate(s) that are downstream from
mTOR and that regulate autophagy throughmodulation of this
interaction.Overall, we showed that RACK1-ATG5 interaction
is indispensable for autophagic activity.
Another question is about the role of RACK1 in the
autophagy pathway. RACK1 is a scaffold/adaptor protein con-
taining WD40 repeats that are important for protein-protein
interactions. Of note, RACK1 was not required for ATG12-
ATG5 or ATG12-5-16 protein complex formation.11 There-
fore, RACK1 possibly functions in the recruitment of other rel-
evant proteins to autophagic isolation membranes near
ATG12-5-16 complexes. Future analyses, including SILAC
assays, will allow the discovery of proteins whose interaction
increases with RACK1 under autophagy-inducing conditions.
In fact, involvement of RACK1 was suggested in Drosophila
studies where loss of RACK1 was associated with attenuated
autophagy responses and glycogen storage defects (14). While
ourmanuscript was in preparation, Zhao et al. (15) showed that
RACK1 was required for hepatocyte autophagy and lipophagy.
They also provided data about the contribution of RACK1 as a
scaffold to VPS34 PI3K complex formation. It is possible that
RACK1 plays a role at different stages of autophagosome bio-
genesis. In our hands, an ATG5-binding deficient mutant of
RACK1 was able to block autophagy, indicating that ATG5-
related functions of the scaffold protein are also rate-limiting
for autophagy activation.
In this study, we characterized RACK1 as a newATG12-5-16
complex component and a novel mTOR-dependent hub in the
regulation of basic autophagy pathways. Overall, we believe
that our results will open the way to a more comprehensive
understanding of autophagy pathway and its molecular control
mechanisms.
11 S. Erbil and D. Gozuacik, unpublished results.
FIGURE 7. RACK1-ATG5 interaction model. A, schematic representation of
human RACK1 (Protein Data Bank code 4AOW). Each WD40 domain (WD1–7)
is in a different color. The seven-bladed -propeller structure is shown. Loca-
tion of the Ser-63 residue is marked in a square. B, schematic model of RACK1
(ProteinDataBankcode4AOW, silver color) andATG5 (ProteinDataBankcode
4GDK, tan color) interaction. Residues found within 3 Å of the other subunit
are selected as binding interface that was rendered in the wire frame surface
model (probe radius, 1.4 Å) by coloring ATG5 residues in green and RACK1 in
yellow. The region around the Ser-63 residue of RACK1 is shown in a red wire
frame and encircled. C, interaction network of predicted RACK1-ATG5 model.
D–F, native and mutated RACK1s (S63A and S63D) were energy-minimized
and equilibrated in MD simulations. Snapshots of the binding interface are
shown with Ser-63, Asp-6, and Lys-38 in licorice models (C, cyan; O, red; N,
blue). Structural integrity of binding interface was probed by the distance of
the ionic interaction between Asp-6 of ATG5 and Lys-38 of RACK1. Although
the wild-type (native) and S63D complexes possessed an intact binding sur-
face with Asp-6–Lys-38 ionic pairing (D and E), S63A showed an extension in
Asp-6–Lys-38 distance (F), implying a weakened interaction of RACK1 and
ATG5. G, r.m.s.d. of the backbone atoms carbon, nitrogen, and -carbon.
Native, wild-type RACK1; S63A, S63A RACK1; S63D, S63D RACK1. H, fluctua-
tions of ATG5 during 5 ns of MD simulations. S63A RACK1 mutant displayed
increased fluctuations at two distinct regions (residues from 32 to 36 and
from 50 to 54), which are found at the binding interface (right panel), the
observation that suggests that S63A RACK1 destabilizes the ATG5-RACK1
complex.
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Experimental Procedures
Plasmid Constructs, siRNAs—To create the pGBKT7-ATG5
yeast two-hybrid bait construct, full-length human ATG5
cDNA insert in the pCI-ATG5 construct was cut with SmaI
enzyme, blunted, and blunt-ligated into the pGBKT7 Y2H bait
vector that was previously cut with NcoI and Klenow-filled.
FLAG-tagged human ATG5 (RC235557), human RACK1
(SC116322), and FLAG-tagged human RACK1 plasmids
(RC505092) were purchased from Origene. Wild-type (WT)
p70S6K plasmid (8984) (21), WT mTOR plasmid (26036) (25),
and shmTOR plasmid (1855) (26) were all provided by Add-
gene. siRNA RACK1 (M-006876-01) and CNT-siRNA
(D-001210-01-20) were purchased from Dharmacon.
Site-directed in Vitro Mutagenesis—Site-directed mutagene-
sis of Thr-39, Ser-63, and Thr-128 residues of RACK1 was
performed using QuikChange site-directed mutagenesis kit
according to the manufacturer’s instructions (Stratagene, cata-
log no. 200519-5). The following primers were used for
mutagenesis: S63D forward, ctgcggggtcacgaccactttgttagt, and
S63D reverse, actaacaaagtggtcgtgaccccgcag; S63A forward, ctg-
cggggtcacgcccactttgttagt, and S63A reverse, actaacaaagtgggcgtga-
ccccgcag; T39D forward, ctctccgcctctcgagataaggacatcatcatgtgg,
and T39D reverse, ccacatgatgatgtccttatctcgagaggcggagag; T39A
forward, atcctctccgcctctcgagataaagccatcatcatgtggaaa, and T39A
reverse, tttccacatgatgatggctttatctcgagaggcggagaggat; T128D for-
ward, attgtctctggatctcgagataaagacatcaagctatggaat, and T128D
FIGURE 8. RACK1-ATG5 interaction is necessary formTOR inhibition- or starvation-induced autophagy in Neuro2A cells. Cells were cultured on cover-
slides and transfected with the empty control vector pcDNA3 or wild-type (wt) or mutant RACK1 (S63A or S63D) constructs. A, 48 h post-transfection, Neuro2A
cells were treated or not with torin 1 (Torin, 250 nM, 3 h) with or without BafA (100 nM, 1 h). Endogenous LC3 proteins were immunostained using anti-LC3
primary antibodies and anti-rabbit IgG Alexa Fluor 488 secondary antibodies. LC3 dot positive cells were quantified as percentage of autophagic cells in total
cell population (mean  S.D. of independent experiments, n  3, *, p  0.05). LC3 and RACK1 protein expression levels in cell lysates were checked in
immunoblots using anti-LC3 and anti-RACK1 antibodies. -Actin was used as loading control. B, representative immunofluorescence pictures of LC3 quanti-
fication experiments in A. White arrows show LC3 dots. C, 48 h post-transfection, Neuro2A cells were cultured in full medium (non-STV) or starved in EBSS (STV,
2 h) with or without BafA (100 nM, 1 h). Endogenous LC3 proteins were immunostained using anti-LC3 primary antibodies and anti-rabbit IgG Alexa Fluor 488
secondary antibodies. LC3 dot positive cells were quantified (mean S.D. of independent experiments, n 3, **, p 0.01; *, p 0.05). LC3 and RACK1 protein
expression levels in cell lysateswere checked in immunoblots using anti-LC3 andanti-RACK1antibodies.-Actinwasused as loading control.D, representative
immunofluorescence pictures of LC3 quantification experiments in C. White arrows show LC3 dots.
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reverse, attccatagcttgatgtctttatctcgagatccagagacaat; and T128A
forward, attgtctctggatctcgagataaagccatcaagctatggaat, and T128A
reverse, attccatagcttgatggctttatctcgagatccagagacaat.
Y2H Screen—For screening, pGBKT7-ATG5 construct was
used as bait, and a thymus cDNA library in the pACT2 vector
was used as prey (Clontech). Screens were performed
according to the protocols provided by the manufacturer.
Briefly, constructs were transformed into the AH109 yeast
strain, and interactions were monitored on selection plates
lacking leucine, tryptophan, histidine, and/or adenine.
After 3–5 days of selection, plasmid inserts in surviving col-
onies were amplified using colony PCR, sequenced, and
characterized.
Cell Culture—HEK293T human embryonic kidney cells and
MEFs were maintained in DMEM high glucose medium
(Sigma, catalog no. 5671), and Neuro2A (N2A) mouse neuro-
blast cells were maintained in DMEM low glucose medium
(Sigma, catalog no. 5546) in a 5% CO2-humidified incubator at
37 °C. Culture media were supplemented with 10% heat-inacti-
vated fetal bovine serum (Biowest, catalog no. S1810-500), anti-
biotics (50 units/ml penicillin and 50 g/ml streptomycin; Bio-
logical Industries, catalog no. 03-031-1B), and L-glutamine (2
mM, Biological Industries, catalog no. BI03-020-1B). In starva-
tion experiments, cells were grown in Earle’s balanced salt solu-
tion (EBSS; Biological Industries, BI02-010-1A). For chemical
induction of autophagy, cells were incubated in media contain-
ing torin 1 (250 nM, Tocris, catalog no. 4247) or rapamycin (200
nM, Sigma, catalog no. R0395) that were dissolved in DMSO
(Sigma, catalog no. VWRSAD2650). Cycloheximide (0.5g/ml,
Sigma, catalog no. 01810) was used in degradation tests. Cal-
ciumphosphate transfectionmethodwas used for gene transfer
into HEK293T cells according to standard protocols. N2A cells
were transfected using polyethyleneimine (PolySciences Inc.,
catalog no. 23966) according to protocols that were described
elsewhere (27).
Cell Lysate Preparation and Immunoblotting—Cells were
washed in PBS and collected by centrifugation, and lysates were
prepared inRIPAbuffer (25mMTris, 125mMNaCl, 1%Nonidet
P-40, 0.1% SDS, 0.5% sodium deoxycholate, 0.004% sodium
azide, pH 8.0) containing complete protease inhibitors (Sigma,
catalog no. P8340) and 1 mM PMSF (Sigma, catalog no. P7626).
Protein concentrations were determined using the Bradford
assay (Sigma, catalog no. B6916). Immunoblotting procedure
was described previously (28). Immunoblots were performed
using antibodies against ATG5 (Sigma, catalog no. A0856),
RACK1 (Santa Cruz Biotechnology, catalog no. sc-17754),
ATG16L1 (MBL, catalog no. PM040), LC3B (Novus, catalog no.
NB100-2331), mTOR (Cell Signaling, catalog no. 2972),
p70S6K (Cell Signaling, catalog no. 9206S), p62 (Abnova, cata-
log no.H00008878), LC3 (Novus, catalog no. 2331), and-actin
(Sigma, catalog no. A5441). ImageJ software was used to quan-
tify protein band intensities (29).
Immunoprecipitation Tests—For the immunoprecipitation
of FLAG-tagged proteins, whole cell lysates (1 mg) were incu-
bated with an anti-FLAG M2 affinity gel (Sigma, catalog no.
A2220). For the immunoprecipitation of endogenous RACK1
or ATG5, protein G Plus-agarose beads (Santa Cruz Biotech-
nology, catalog no. sc-2002) or protein A Plus-agarose beads
(Santa Cruz Biotechnology, catalog no. sc-2001) were cou-
pled to 10 g/ml anti-RACK1 or anti-ATG5 antibodies,
respectively. Normal rabbit serum (Santa Cruz Biotechnol-
ogy, catalog no. sc-2027) or normal mouse serum (Santa
Cruz Biotechnology, catalog no. sc-45051) was used as neg-
FIGURE 9. Rescue experiments with RACK1 mutant constructs following
siRNA knockdown of RACK1. A, HEK293T cells were transfected with siR-
ACK1 or control siRNA (CNT siRNA). The effect of siRNAs was checked by
immunoblotting using anti-RACK1 antibodies. Molecular mass is shown in
kilodaltons (kDa). -Actin was used as loading control. Band intensities were
quantified using ImageJ. B, HEK293T cells were grown onto coverslides and
transfected with the empty control vector pcDNA3 or wild-type (wt) or
mutant RACK1 (S63A or S63D) constructs. 48 h post-transfection, HEK293T
cells were treated or not with torin 1 (Torin, 250 nM, 3 h) with or without E64D
(E64D, 10g/ml, 1 h) and PepA (pepstatin A, 10g/ml, 1 h). Endogenous LC3
proteins were immunostained using anti-LC3 primary antibodies and anti-
rabbit IgG Alexa Fluor 488 secondary antibodies. LC3 dot positive cells were
quantified as percentage of autophagic cells in total cell population (mean
S.D. of independent experiments, n  3, **, p  0.01; *, p  0.05). LC3 and
RACK1 protein expression levels were detected by immunoblotting using
anti-LC3 and anti-RACK1 antibodies. -Actin was used as loading control. C,
representative immunofluorescence pictures of LC3 quantification experi-
ments in A. White arrows show LC3 dots.
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ative control. Samples were analyzed by immunoblotting as
described.
GST Pulldown Assay—For the pulldown assays, 25 l of glu-
tathione-Sepharose 48 beads (GE Healthcare, catalog no.
17-0756-01) in Tris-HCl (20 mM, pH 7.5) were initially incu-
bated (overnight at 4 °C) with 5 ng of GST-tagged ATG5
recombinant protein (Abnova, H00009474). Following three
washes in the same buffer, beads were incubated for 8 h at 4 °C
with 5 ng of His-tagged RACK1 recombinant protein (Abcam,
catalog no. ab119442). Samples were analyzed by immunoblot-
ting as described.
Immunofluorescence Analyses—2  105 cells were cultured
on poly-L-lysine (Sigma, catalog no. P8920)-coated glass cover-
slides. Following 2 h of starvation in the EBSS medium and
incubation for 3 hwith torin 1 (250nM,Tocris, catalog no. 4247)
or 16 hwith rapamycin (200 nM, Sigma, catalog no. R0395), cells
were fixed in ice-cold 4% paraformaldehyde/PBS and permea-
bilized in PBS with 0.1% BSA (Sigma, catalog no. A4503) and
0.1% saponin (Sigma, 84510). Immunostaining was per-
formed using anti-RACK1 antibody (Santa Cruz Biotechnol-
ogy, catalog no. sc-17754), anti-ATG5 antibody (Sigma, cat-
alog no. A0856), or anti-LC3 antibody (Sigma, L7543)
followed by incubation with anti-mouse IgG Alexa Fluor 488
(Invitrogen, catalog no. A11001), anti-rabbit IgGAlexa Fluor
488 (Invitrogen, catalog no. A11008), anti-rabbit IgG Alexa
Fluor 568 (Invitrogen, catalog no. A11011). Coverslides were
mounted onto glass slides, and samples were analyzed using
a Carl Zeiss LSM 710 confocal microscope (Zeiss, Germany).
Quantitative LC3 Analyses—LC3 dot positivity was quanti-
fied following 2 h of starvation in the EBSS medium or 3 h of
incubation with torin 1 (250 nM, Tocris, catalog no. 4247) or
16 h of incubation with rapamycin (200 nM, Sigma, R0395), in
the presence or absence of 1 h of incubation with E64D (10
g/ml, Santa Cruz Biotechnology, 201280), pepstatin A (10
g/ml, Sigma, catalog no. p5318), or bafilomycin A (100 nM,
Sigma, catalog no. B1793). 10 LC3 dots per cell were consid-
ered as the threshold for basal autophagy. Minimum 150
cells were counted for each condition, and results were
expressed as percentage of LC3 dot-positive cells in total cell
population (30).
Gel Filtration Tests—For separation of proteins, a Super-
oseTM 6 10/300 GL column (separation range 5–5000 kDa) was
used (GEHealthcare, catalog no. 17-5172-01). Sigmamolecular
weight kit was used for the calibration of the system (Sigma,
catalog no.MWGF-1000). Chromatography analyses were per-
formed using an AKTA Prime FPLC system (AKTA FPLC
UPC900/P920 System/Frac 900 fraction collector, GE Health-
care). For separation of proteins, a modification of a previously
reported protocol was used (12). Briefly, a chromatography col-
umn was calibrated with sonicated balancing buffer (1:1, 0.05%
glycerol PBS/RIPA buffer) to optimize flux, absorbance, and
pressure parameters (pressure, 1.5 MPa; flux velocity, 0.5
ml/min; fraction volume, 0.5 ml; loop volume, 500 l). Protein
extracts from HEK293T or N2A cells (5–7.5 mg of protein)
were loaded in a 500-l volume, and 500-l fractions were col-
lected. The column was washed with 36 ml of deionized water
(3 column volume) and re-calibrated with sonicated balanc-
ing buffer after each sample. Immunoblotting of collected frac-
tions was performed as described.
SILAC Labeling—Tri-SILAC labeling of FLAG-tagged
ATG5-expressing HEK293T cells was carried out using SILAC
medium (DMEM without L-lysine and L-arginine (Thermo
Fisher Scientific, catalog no. 89985) supplemented with peni-
cillin/streptomycin (100 units/ml, 100 g/ml; PAN Biotech,
catalog no. 06-07100), L-glutamine (PAN Biotech, catalog no.
P04-80100), and 10% dialyzed fetal calf serum (Gibco, 26400-
044)). Heavy labeling was carried out with the addition of 42
g/ml L-arginine-13C615N4-hydrochloride (Arg-10) (Sigma-
Isotec, catalog no. 608033) and 40 g/ml L-lysine-13C615N2-
hydrochloride (Lys-8) (Sigma-Isotec, catalog no. 608041).
Medium labeling was performed following addition of 42
g/ml L-arginine-13C6-hydrochloride (Arg-6) (Cambridge Iso-
tope Laboratories Inc., Andover MA., catalog no. CLM-2265)
and 40g/m L-lysine- 4,4,5,5-d4-hydrochloride (Lys-4) (Sigma-
Isotec, catalog no. 616192). Light labeling was achieved using
corresponding non-labeled amino acids L-arginine (Sigma, cat-
alog no. 11039) and L-lysine (Sigma, catalog no. L8662). All
three types of SILACmediawere supplementedwith 112g/ml
L-proline (Fluka, catalog no. 81709) (31). Labeling was contin-
ued for five cell doublings. Labels were swapped in independent
experiments.
Liquid Chromatography (LC)-Tandem Mass Spectrometry
(MS/MS) Sample Preparation—Labeled cells were collected by
centrifugation, washed in PBS, and lysed in a modified RIPA
buffer (50mMTris, pH 7.5, 150mMNaCl, 1%Nonidet P-40, and
0.25% sodium deoxycholate) with complete protease inhibitors
(Roche Applied Science, catalog no. 10269700). Protein con-
centrations were determined using BCA assay (BCA kit, Pierce,
catalog no. 23225). Overexpressed FLAG-tagged ATG5 was
immunoprecipitated from 2.5 mg of whole cell lysates using an
anti-FLAG M2 affinity gel (Sigma, catalog no. A2220). Beads
were incubated at 75 °C for 30 min in Laemmli buffer (70%
Tris/SDS, pH 6.8, 30% glycerol, 10% SDS, and bromphenol
blue) with 1 mM DTT, then 5.5 mM iodoacetamide was added,
and sampleswere further incubated at room temperature for 30
min, allowing reduction and alkylation. Sampleswere separated
by electrophoresis in 4–12% Bis-Tris gels (NuPAGENovex,
catalog no. NP0335) and using 20MOPS-SDS running buffer
(NuPAGENovex, catalog no. NP001) with 0.07% antioxidant
supplement (NuPAGENovex, catalog no. NP0005). The gel
was incubated for 10 min in fixing solution (40% double dis-
tilled H2O, 50% methanol, 10% acetic acid), and protein bands
were visualized using NuPAGENovex Stainer solutions
(NuPAGENovex, catalog nos. 46-7015 and 46-7016). Protein
bands were cut from gels and washed in ABC buffer (100 mM
ammonium bicarbonate, pH 7.5) followed by incubation
with ethanol (HPLC grade). Then, cold trypsin solution
(Promega, catalog no. V511C) was added onto dried gel
cubes followed by a 20-min incubation at room temperature
and overnight incubation at 37 °C. Trypsin activity was
blocked by adding 2% trifluoroacetic acid (TFA). Following
ethanol washes, supernatants were concentrated using
SpeedVac (ThermoScientific). Then Buffer A (0.5% acetic
acid) and Buffer A/A* (75/25%; Buffer A*, 3% acetonitrile,
0.3% TFA) was added at a 3:1 ratio. Peptides were eluted
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from StageTips with C18 material (3M Empore catalog no.
2215) using Buffer B (0.5% acetic acid, 80% acetonitrile) (32).
Eluted samples were concentrated using SpeedVac, and
ready-to-inject peptide samples were obtained following
addition of 10 l of Buffer A/A*.
LC-MS/MS—Nanoscale HPLC was performed using either
an Agilent 1200 or an Eksigent NanoLCultra connected on
line to an LTQ-Orbitrap XL (Thermo Scientific) setup and a
15-cm in-house-packed fused silica emitter microcolumn
(SilicaTip PicoTip; New Objective) filled with reverse-phase
ReproSil-Pur C18-AQ beads with the size of 3.5 m and
inner diameter of 20 m (Dr. Maisch, GmbH, Germany).
Peptides were separated over a linear gradient of 10–30%
acetonitrile in 0.5% acetic acid with a flow rate of 250 nl/min.
A full-scan acquisition was carried out in the FT-MS part of
the mass spectrometer in the range ofm/z 350–2000 with an
automatic gain control target value of 106 and at a resolution
of 60,000 at m/z 400. AGC target value was set to 5000, ion
selection thresholds were set to 1000 counts, and a maxi-
mum fill time of 100 ms was used to sequentially perform
MS/MS on the five most intense ions in the full scan (Top5)
in the LTQ in a data-dependent mode. Wide band activation
was enabled with an activation q  0.25 applied for 30 ms at
a normalized collision energy of 35%. Unassigned or single
charged ions were excluded from MS/MS. Dynamic exclu-
sion was applied to reject ions from repeated MS/MS selec-
tion for 45 s.
MS Data Analysis—LC-MS/MS raw files, belonging to three
biological replicates, were processed altogether in MaxQuant
version 1.4.0.8 with default parameters using UniProt human
database (33). MaxQuant was used to filter the identifications
for a false discovery rate below 1% for peptides, sites, and pro-
teins using forward-decoy searching. Match between runs was
enabled.
Molecular Dynamics Simulations—MD simulations were
performed using the predicted complex structure of RACK1-
ATG5 obtained from docking step and its RACK1 mutants
S63A and S63D. The protein complexes were placed in water
boxes with dimensions of 115  75  80 Å3, and then the
systems were ionized with a 100 mM NaCl solution to a neu-
tral state. The resulting systems composed of63,000 atoms
were used in MD simulations using the NAMD program (34)
with the CHARMM22 parameters (35, 36), which included a
correction map for backbone atoms (37, 38). Water mole-
cules within the system were treated explicitly using the
TIP3P model (39). An NPT ensemble was used in MD sim-
ulations with periodic boundary conditions, and the long
range Coulomb interactions were computed using the parti-
cle-mesh Ewald algorithm. Pressure was maintained at 1
atm, and temperature was maintained at 310 K using the
Langevin pressure and temperature coupling. A time step of
2 fs was used in all MD simulations. The systems are fully
energy-minimized in 20,000 steps and equilibrated under
constant temperature and volume for 5 ns. Visual molecular
dynamics was used for the analysis of trajectories and visu-
alization of all of the structures. The r.m.s.d. for the back-
bone atoms (carbon, nitrogen, and -carbon) and residue-
wise root mean square fluctuations of C atoms were
calculated as measures of equilibration and flexibility,
respectively.
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